Three-Year Follow-Up From checkMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Felip, Enriqueta [1 ]
Gettinger, Scott [2 ]
Burgio, Marco Angelo [3 ]
Antonia, Scott J. [4 ]
Holgado, Esther [5 ]
Spigel, David [6 ]
Arrieta, Oscar [7 ]
Domine, Manuel [8 ]
Aren Frontera, Osvaldo [9 ]
Brahmer, Julie [10 ]
Chow, Laura Q. [11 ]
Crino, Lucio [12 ]
Butts, Charles [13 ]
Coudert, Bruno [14 ]
Horn, Leora [15 ]
Steins, Martin [16 ]
Geese, William J. [17 ]
Li, Ang [17 ]
Healey, Diane [17 ]
Vokes, Everett E. [18 ]
机构：
[1] Hosp Univ Vall Hebron, Barcelona, Spain
[2] Yale Canc Ctr, New Haven, CT USA
[3] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Hosp Madrid, Madrid, Spain
[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[7] Inst Nacl Cancerol, Mexico City, DF, Mexico
[8] Fdn Jimenez Diaz, Madrid, Spain
[9] Ctr Int Estudios Clin, Santiago, Chile
[10] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[11] Univ Washington, Seattle, WA 98195 USA
[12] Osped Perugia, Perugia, Italy
[13] Cross Canc Inst, Edmonton, AB, Canada
[14] Ctr Georges Francois Leclerc, Dijon, France
[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[16] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Univ Chicago Med & Biol Sci, Chicago, IL USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213
引用
收藏
页码：142 / 143
页数：2
相关论文
共 50 条
  • [21] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
    Paz-Ares, Luis
    Horn, Leora
    Borghaei, Hossein
    Spigel, David R.
    Steins, Martin
    Ready, Neal
    Chow, Laura Quan Man
    Vokes, Everett E.
    Felip, Enriqueta
    Holgado, Esther
    Barlesi, Fabrice
    Kohlhaeufl, Martin
    Rodriguez, Oscar
    Burgio, Marco Angelo
    Fayette, Jerome
    Gettinger, Scott N.
    Harbison, Christopher
    Dorange, Cecile
    Finckenstein, Friedrich Graf
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [22] Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SO) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017
    Farsaci, Benedetto
    Geese, William J.
    Desai, Kaushal D.
    Jin, Chelsea
    Antonia, Scott J.
    Lena, Herve
    Horn, Leora
    Planchard, David
    Reckamp, Karen L.
    Stinchcombe, Thomas E.
    Gettinger, Scott
    Borghaei, Hossein
    Hellmann, Matthew D.
    Harbison, Christopher
    Xu, Dong
    Blackwood-Chirchir, M. Anne
    Rizvi, Naiyer
    CANCER RESEARCH, 2016, 76
  • [23] Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
    Reck, Martin
    Brahmer, Julie
    Bennett, Bryan
    Taylor, Fiona
    Penrod, John R.
    DeRosa, Michael
    Dastani, Homa
    Spigel, David R.
    Gralla, Richard J.
    EUROPEAN JOURNAL OF CANCER, 2018, 102 : 23 - 30
  • [24] Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials
    Venkatachalam, Meena
    Stenehjem, David D.
    Pietri, Guilhem
    Penrod, John R.
    Korytowsky, Beata
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
    Borghaei, H.
    Johnson, M. L.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Dumoulin, D.
    De Marinis, F.
    Reynolds, C. H.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Flandin, A. C. Madroszyk
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
  • [26] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [27] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Qiao Liu
    Xia Luo
    Liubao Peng
    Lidan Yi
    Xiaomin Wan
    Xiaohui Zeng
    Chongqing Tan
    Clinical Drug Investigation, 2020, 40 : 129 - 137
  • [28] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Liu, Qiao
    Luo, Xia
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Zeng, Xiaohui
    Tan, Chongqing
    CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
  • [29] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)
    Thomas, M.
    Kohlhaeufl, M.
    Reck, M.
    Engel-Riedel, W.
    Kortsik, C.
    Bullinger, L.
    Schneider, C. -P.
    Felip, E.
    Brahmer, J.
    Vokes, E.
    Gettinger, S.
    Geese, W.
    Yoon, D.
    Healey, D.
    Li, A.
    Eberhardt, W. E. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137
  • [30] Impact of of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study
    Reck, Martin
    Taylor, Fiona
    Penrod, John R.
    DeRosa, Michael
    Morrissey, Laura
    Dastani, Homa
    Orsini, Lucinda
    Gralla, Richard J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 194 - 204
12345